rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2020-198-206rsp-2878Research ArticleФОРУМ МОЛОДЫХ УЧЕНЫХYOUNG SCIENTISTS FORUMВзаимосвязь онкологических и ревматических заболеванийTHE RELATIONSHIP BETWEEN OF CANCERS AND RHEUMATIC DISEASEShttps://orcid.org/0000-0003-0576-4870КолтаковаА. Д.KoltakovaA. D.
младший научный сотрудник лаборатории микроциркуляции и воспаления (научный руководитель – д.м.н. А.М. Лила)
115522, Москва, Каширское шоссе, 34А
koltakova.a.d@gmail.comФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202026042020582198206Copyright © Колтакова А.Д., 20202020Колтакова А.Д.Koltakova A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2878онкологические заболеванияревматические заболеванияпаранеопластические синдромыcancersrheumatic diseasesparaneoplastic syndromesReferencesKankeleit H. Uber primare nichteirige Polymyositis. Dtsch Arch Klin Med. 1916;120:335-49.Kankeleit H. Uber primare nichteirige Polymyositis. Dtsch Arch Klin Med. 1916;120:335-49.Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0Kankeleit H. Uber primare nichteirige Polymyositis. Dtsch Arch Klin Med. 1916;120:335-49.Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;17;357(9255):539-45. doi: 10.1016/S0140-6736(00)04046-0Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886Roxburgh C. Inflammation and cancer: friend or foe. Ann Rheum Dis. 2018;77:3. doi: 10.1136/annrheumdis-2018-eular.7859Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002Van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xLlorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002Антелава ОА, Хелковская-Сергеева АН, Чичасова НВ и др. Миозит, ассоциированный со злокачественными опухолями. Научно-практическая ревматология. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, et al. Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum. 2007;37(1):31-8. doi: 10.1016/j.semarthrit.2007.01.002Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292Васильев ВИ, Пробатова НА, Тупицын НН и др. Лимфопролиферативные заболевания при болезни Шегрена. Онкогематология 2007;3;16-26.Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Crane GM, Powell H, Kostadinov R, et al. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget. 2015;6(32):33849e6. doi: 10.18632/oncotarget.5292Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9e21. doi: 10.1002/art.25061Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Upadhyay S, Sharma N, Gupta KB, Dhiman M. Role of immune system in tumor progression and carcinogenesis. J Cell Biochem. 2018;119(7):5028-42. doi: 10.1002/jcb.26663doi: 10.1097/BOR.0000000000000329Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Vlagea A, Falagan S, Gutierrez-Gutierrez G, et al. Antinuclear antibodies and cancer: A literature review. Crit Rev Oncol Hematol. 2018;127:42-9. doi: 10.1016/j.critrevonc.2018.05.002Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/S0065-2776(08)60641-0Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.doi: 10.1136/ard.2004.032995Cavagna L, Prisco E, Montecucco C, Caporali R. Association between antidsDNA titre increase and thymoma relapse. Clin Exp Rheumatol. 2011;29(3):599-600.Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-ySyrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20(6B):4351-3.Virik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xPignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30.Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384doi: 10.1097/00000478-200401000-00001Pignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384Luz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xPignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology. 2013;2(12):e27384. doi: 10.4161/onci.27384Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-7. doi: 10.1126/science.1246886Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110. doi:10.1186/s13075-017-1303-3Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Van der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EVan der Vlist M, Kuball J, Radstake TR, et al. Immune checkpoints and rfheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol. 2016;12(10):593-604. doi: 10.1038/nrrheum.2016.131Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282-91. doi: 10.3899/jrheum.140566Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.Насонов ЕЛ. Ингибиция иммунных контрольных точек и аутоиммунитет: ревматологические проблемы. Научно-практическая ревматология. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oAndras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438-44.Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xWakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xWakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xWakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xWakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xWakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xWakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xWakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xWakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xWakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xWakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xWakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol. 2002;41(11):729-34. doi: 10.1046/j.1365-4362.2002.01648.xAntelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)Antelava OA, Khelkovskaya-Sergeeva AN, Chichasova NV, et al. Myositis associated with malignant tumors. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):289-98. doi: 10.14412/1995-4484-2016-289-298 (In Russ.)Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Furlong MA, Motamedi K, Laskin WB, et al. Synovial-type giant cell tumors of the vertebral column: a clinicopathologic study of 15 cases, with a review of the literature and discussion of the differential diagnosis. Hum Pathol. 2003;34(7):670-9. doi: 10.1016/s0046-8177(03)00250-8Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a metaanalysis. Arthritis Res Ther. 2015;17:212. doi: 10.1186/s13075-015-0728-9Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Liang Y, Yang Z, Qin B, Zhong R. Primary Sjö gren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6. doi: 10.1136/annrheumdis-2013-203305Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)Vasil'ev VI, Probatova NA, Tupitsyn NN, et al. Lymphoproliferative diseases in Sjö gren's disease. Onkogematologiya. 2007;(3):16-26 (In Russ.)Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. doi: 10.1016/j.jaut.2012.12.009Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: a meta-analysis of observational studies. PLoS One. 2015;10(5):e0126016. doi: 10.1371/journal.pone.0126016Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913e21. doi: 10.1002/art.37969Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum. 1999;29(1):43-55. doi: 10.1016/S0049-0172(99)80037-7Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Manzini CU, Colaci M, Ferri C, et al. Paraneoplastic rheumatic disorders: a narrative review. Reumatismo. 2018 Dec 20;70(4):199-211. doi: 10.4081/reumatismo.2018.1069Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J Rheumatol. 2002;29:2143-7.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol. 1993;20:1335-9.Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Haugeberg G, Dovland H, Johnsen V. Increased frequency of malignancy found in patients presenting with new-onset polymyalgic symptoms suggested to have polymyalgia rheumatica. Arthritis Rheum. 2002;47:346-47. doi: 10.1002/art.10402Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancerassociated myositis. Ann Rheum Dis. 2007;66(10):1345-9. doi: 10.1136/ard.2006.068502Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-9. doi: 10.1002/art.22164Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299-308. doi: 10.1212/WNL.0000000000002863Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Trallero-Araguas E, Rodrigo-Pendas J, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523-32. doi: 10.1002/art.33379Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specifc autoantibodies. Curr Opin Rheumatol. 2016;28(6):636-44.doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329doi: 10.1097/BOR.0000000000000329Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inяammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;1(5):710-3. doi: 10.1136/annrheumdis-2011-200697Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Rogers A, Chung L, Li S, et al. The cutaneous and systemic fndings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69(12):1909-14. doi: 10.1002/acr.23210Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specifc antibody. Brain. 2016;139(Pt 8):2131-5. doi: 10.1093/brain/aww054Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72. doi: 10.1007/s11926-015-0548-6Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Kadoya M, Hida A, Hashimoto Maeda M, et al. Cancer association as a risk factor for anti-HMGCR antibodypositive myopathy. Neurol Neuroimmunol Neuroinflam. 2016;3(6):e290. doi: 10.1212/NXI.0000000000000290Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57(8):1473-80. doi: 10.1002/art.23085Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Park HJ, Ranganathan P. Neoplastic and paraneoplastic vasculitis, vasculopathy, and hypercoagulability. Rheum Dis Clin North Am. 2011;37(4):593-606. doi: 10.1016/j.rdc.2011.09.002Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Hasler P, Kistler P, Gerber H. Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995;25(2):134-42. doi: 10.1016/S0049-0172(95)80026-3Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014;17(6):640-5. doi: 10.1111/1756-185X.12277Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis. 2008;67:244-7. doi: 10.1136/ard.2007.070086Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Callemeyn J, van Haecke P, Peetermans WE, Blockmans D. Clubbing and hypertrophic osteoarthropathy: insights in diagnosis, pathophysiology, and clinical significance. Acta Clin Belg. 2016 Jun;71(3):123-30. doi: 10.1080/17843286.2016.1152672Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Zhang Z, Zhang C, Zhang Z. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721-8. doi: 10.1002/path.1565Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Hah YS, Jun J, Lee S, et al. Vascular endothelial growth factor stimulates osteoblastic differentiation of cultured human periosteal-derived cells expressing vascular endothelial growth factor receptors. Mol Biol Rep. 2011;38(2):1443-50. doi: 10.1007/s11033-010-0249-1Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89-94. doi: 10.1016/j.semarthrit.2008.11.006Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653-5.doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995doi: 10.1136/ard.2004.032995Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246-8. doi: 10.1007/s10067-003-0840-0Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Tabeya T, Sugaya T, Suzuki C, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281-5. doi: 10.3109/14397595.2013.857836Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yOriguchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584-8. doi: 10.1007/s10165-011-0556-yJohnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Johnson EW, Pannozzo AN. Management of shoulder-hand syndrome. JAMA. 1966;195(2):108-10. doi: 10.1001/jama.195.2.108Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Martorell EA, Murray PM, Peterson JJ, et al. Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am. 2004;29:654-60. doi: 10.1016/j.jhsa.2004.04.012Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Yogarajah M, Soh J, Lord B, et al. Palmar fasciitis and polyarthritis syndrome: a sign of ovarian malignancy. J R Soc Med. 2008;101(9). doi: 10.1258/jrsm.2008.080060Virik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xVirik K, Lynch KP, Harper P. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J. 2002;32(1-2):50-1. doi: 10.1046/j.1445-5994.2002.00153.xMcCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.McCance RA. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16(1):33-46.Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;8;18(3):R53-77. doi: 10.1530/ERC-11-0006Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28(1):1-30. doi: 10.1097/00000478-200401000-00001Luz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xLuz F, Gaspar T, Kalil-Gaspar N, et al. Multicentric reticulohistiocytosis. J Eur Acad Dermatol Venereol. 2001;15(6):524-31. doi: 10.1046/j.1468-3083.2001.00362.xMatejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Matejicka CG, Morgan J, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6. doi: 10.1002/art.10781Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Shah A, Diehl LF, St Clair EW. T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. Clin Immunol. 2009;132(2):145-52. doi: 10.1016/j.clim.2009.03.515Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Prochorec-Sobieszek M, Rymkiewicz G, Makuch-Lasica H, et al. Characteristics of T-cell large granular lymphocyte proliferations associated with neutropenia and inflammatory arthropathy. Arthritis Res Ther. 2008;10(3):R55. doi: 10.1186/ar2424Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997;40(5):884-92. doi: 10.1002/art.1780400516Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Goldenberg DL. Septic arthritis. Lancet. 1998;351:197-202. doi: 10.1016/S0140-6736(97)09522-6Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Fallon SM, Guzik HJ, Kramer LE. Clostridium septicum arthritis associated with colonic carcinoma. J Rheumatol. 1986;13(3):662-3.Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Cuellar ML, Silveira LH, Espinoza LR. Fungal arthritis. Ann Rheum Dis. 1992;51(5):690-7. doi: 10.1136/ard.51.5.690Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Meier JF, Beekmann SE. Mycobacterial and fungal infections of bone and joints. Curr Opin Rheumatol. 1995;7:329-36. doi: 10.1097/00002281-199507000-00011Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Kim MJ, Ye YM, Park HS, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006 Jul;33:1364-8.Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11:768-70. doi: 10.1200/JCO.1993.11.4.768Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19:2767.Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877-83. doi: 10.1200/JCO.2007.10.7573Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005 Aug;93 Suppl 1:S16-22. doi: 10.1038/sj.bjc.6602691Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park). 2005 Apr;19:651-8.Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006 Apr;26:481-8. doi: 10.1007/s00296-005-0059-2Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Koch B, Kranzhofer N, Pfreundschu M, et al. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26(6):673-5. doi: 10.1038/sj.bmt.1702565Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Aljada IS, Crane JK, Corriere N, et al. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol. 1999 Jun;37:2106-8. doi: 10.1128/JCM.37.6.2106-2108.1999Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EIoannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43(7):1431-42. doi: 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-EHory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Hory B, Blanc D, Saint-Hilier Y. Systemic lupus erythematosuslike syndrome induced by alpha-interferon therapy. Eur J Med. 1992;1(6):379.Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and nonrheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford). 2005 Aug;44(8)1016-20. doi: 10.1093/rheumatology/keh668Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol. 1992 Feb;19:294-6.Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004;51(2 Suppl.):S73e6. doi: 10.1016/j.jaad.2001.07.001Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Vogelsang GB, Pavletic SZ. Chronic graft versus host disease: Interdisciplinary management. Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo: Cambridge University Press; 2009. P. 56-62.Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford). 2003;42(1):34-9. doi: 10.1093/rheumatology/keg025Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221. doi: 10.1371/journal.pone.0160221Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Nasonov EL. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(1):5-9. doi: 10.14412/1995-4484-2018-5-9 (In Russ.)Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Sebastiani GD, Scirocco C, Galeazzi M. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. Autoimmun Rev. 2019 Aug;18(8):805-13. doi: 10.1016/j.autrev.2019.06.005Esteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-oEsteva-Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer. 1995;76(7):1219-23. doi: 10.1002/1097-0142(19951001)76:7<1219::aid-cncr2820760719>3.0.co;2-o
The authors declare that there are no conflicts of interest present.